A Phase-1, Parallel-Design, Open-Label, Randomized, Multiple-Dose Escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of LY3549492 in Healthy Participants With Overweight or Obesity
Status: Recruiting
Location: See all (3) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
The purpose of this study is to see how safe and well-tolerated the drug LY3549492 is and how it behaves in the body, when given in multiple doses to healthy people who are overweight or have obesity. Participation in the study will last approximately 8 weeks.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: t
View:
• Have a hemoglobin A1c level of less than 6.5 percent (%) at screening.
• Have a body mass index (BMI) of 25.0 to 45.0 kilogram per square meter (kg/m²), inclusive, at screening
• Participants assigned male at birth (AMAB) or participants assigned female at birth (AFAB) who are individual of childbearing potential (INOCBP) Contraceptive use by participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Locations
United States
Florida
Fortrea Clinical Research Unit
RECRUITING
Daytona Beach
Texas
Fortrea Clinical Research Unit
RECRUITING
Dallas
Wisconsin
Fortrea Clinical Research Unit
COMPLETED
Madison
Contact Information
Primary
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
LillyTrials@Lilly.com
1-317-615-4559
Backup
Physicians interested in becoming principal investigators please contact
clinical_inquiry_hub@lilly.com
Time Frame
Start Date: 2025-10-27
Estimated Completion Date: 2026-07
Participants
Target number of participants: 120
Treatments
Experimental: LY3549492 (Treatment Group 1)
LY3549492 administered orally.
Experimental: LY3549492 (Treatment Group 2)
LY3549492 administered orally.
Experimental: LY3549492 (Treatment Group 3)
LY3549492 administered orally.
Experimental: LY3549492 (Treatment Group 4)
LY3549492 administered orally.
Related Therapeutic Areas
Sponsors
Leads: Eli Lilly and Company